

New Products - Mifepristone Linepharma

Mifepristone Linepharma (**mifepristone**) contains a synthetic steroid with an antiprogesterone action as a result of competition with progesterone at the progesterone receptors. Oral administration was shown to inhibit the action of endogenous or exogenous progesterone in multiple species (rat, mouse, rabbit, dog and monkey). This action is manifested in the form of pregnancy termination. It is indicated in females of childbearing age for the medical termination of a developing intra-uterine pregnancy in sequential combination with a prostaglandin analogue up to 49 days of gestation. It is also indicated in preparation for the action of registered prostaglandin analogues that are indicated for the termination of pregnancy for medical reasons beyond the first trimester. It is contraindicated in all indications in those with chronic adrenal failure; severe disease (e.g. asthma uncontrolled by treatment) necessitating exogenous steroid administration; known or suspected hypocoagulation diseases, treatment with anticoagulants. It is contraindicated in the medical termination of a developing intrauterine pregnancy in those with uncertainty about pregnancy age; suspected ectopic pregnancy; contraindication to the prostaglandin analogue selected. It is also contraindicated in the preparation for the action of prostaglandin analogues during terminations for medical reasons when there are contraindications to the prostaglandin analogue selected. Mifepristone Linepharma is available as a 200 mg tablet.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.